Facilitators and barriers to health care access amongst people using image and performance enhancing drugs in Wales. by unknown
Facilitators   and   Barriers  to   Health   Care   Access   
Amongst   people   using   Image  and   Performance   
Enhancing   Drugs   in  Wales
Findings   &   
Outcomes   
report
About Public Health Wales
  
Public Health Wales exists to protect and improve health and wellbeing and reduce health ine-
qualities for people in Wales.  We work locally, nationally and internationally, with our partners and 
communities.
  
The Substance Misuse Programme works to address both the current and emerging public health 
threats in Wales and in line with the overarching strategic objective to ‘reduce health inequalities, and 
prevent or reduce communicable and non-communicable disease, wider harms and premature death 
related to drugs and alcohol’.
Substance Misuse Programme
Public Health Wales





About Public Health Institute
The Public Health Institute at Liverpool John Moores University specialises in applied research 
addressing health issues at all levels from policy development to service delivery. Public Health In-
stitute is committed to a multidisciplinary approach to public health and works in partnership with 
health services, local authorities, judicial bodies, environmental services and community groups.
Influencing health service design and delivery, as well as health related policy, the Public Health 
Institute’s research has been at the forefront of the development of multi-agency strategies to pro-
mote and protect public health.
Public Health Institute
Liverpool John Moores University





The research team and Public Health Wales would like to thank all those that contributed to this 
work. 
Research Team: 
Public Health Wales: Josie Smith, Dean Acreman, Gareth Morgan.
Public Health Institute, Liverpool John Moores University: Prof Vivian Hope, Dr Conan Leavy.
Suggested citation: 
V Hope, C Leavy, G Morgan, D Acreman, D Turner and J Smith. 
Facilitators and barriers to health care access amongst people using image and performance 
enhancing drugs in Wales: Findings & Outcomes Report. Public Health Wales, 2020
Contents
1 Executive summary                   1
      1.1 Key findings                 1
      1.2  Recommendations                       1
2 Introduction                 3
      2.1 Background & context                                              3
      2.2 The study                 5
3 Method & Participants               6
      3.1 Interviews with people using  
 anabolic-androgenic steroids              7
      3.2 Interviews with those providing services             7
      3.3 Evidence Gathering & Synthesis Event                7
4 Findings and observations               9
      4.1 Motivations, knowledge and information             9
      4.2 Identity, stigma, and service engagement        14
      4.3 Service delivery, practices and policy         18
      4.4 Suggested recommendations for service improvement 25
      4.5 Consensus on preliminary recommendations
 for service improvement and development        26
5 Conclusions & Recommendations         29
6 References            30
  
Building on the national surveys of image and performance enhancing drug use undertaken in both 
2015 and 2016 (available at: www.ipedinfo.co.uk), a qualitative research project was undertaken in 
Wales to explore the barriers and facilitators to health care access amongst people using anabolic-
androgenic steroids (AAS) and other image and performance enhancing drugs (IPEDs).  The aim of 
this research was to identify low cost (<£5k) or no cost service improvements and interventions to 
encourage early engagement with health and related services by people using IPEDs in order to 
reduce health harms, be they physical, psychological and/or social. 
 
This study utilised data and ideas gathered through semi-structured qualitative interviews with 
individuals using anabolic–androgenic steroids and those providing community-based health and 
related services that should be accessed by this group and an Evidence Gathering and Synthesis 
Event which involved a wide range of stakeholders.  Ideas for services improvements identified 
through these activities were then synthesised into a number of recommendations.
Whilst this work was undertaken in Wales, in light of the findings from the previous IPED surveys 
and extensive engagement with this population across England, Scotland and Wales, the findings 
and recommendations are considered to be generalizable to the wider UK population using AAS 
and other image and performance enhancing drugs.
Within this study reported durations of AAS use varied from a couple of years to several decades 
and motivations for use were varied and often changed over time. However, it was often perceived 
by individuals that their motivating factors were often undervalued or misunderstood by health 
professionals, with little credit being given to other lifestyle commitments e.g. diet and training. 
 
All participants using AAS had experienced or witnessed harmful side effects linked in part or fully 
to AAS use, however the majority of participants minimised the health risks. Concerns were raised 
by all participants groups regarding the availability and accessibility of evidence based information 
for both people who use AAS and other IPEDs and frontline professionals. 
Most participants perceived their AAS use to be problematic in terms of incurring social risk, many 
felt judged by friends, family, work colleagues, and health care services. This negatively impacted 
on their willingness to disclose AAS use to health professionals and to seek appropriate healthcare. 
Facilitators to service engagement included non-judgemental and knowledgeable staff who were 
willing to acknowledge participants’ own expertise and offer targeted services.
It was widely recognised by all that there was a growing use of online technologies by individuals 
using AAS as a method in obtaining injecting paraphernalia and accessing metabolic testing. Such 
services were commonly viewed as more convenient and accessible when compared to traditional 












Government bodies, academic institutions and health services to provide resources and undertake 
a review with the aim of developing the evidence base on the use of online technologies (including 
social media) to facilitate effective health service engagement and e-clinics. This work should include 
online advice and triage clinics targeted towards young people using AAS currently not engaged 
with existing services
Public health bodies, community substance misuse leads and commissioners to develop best prac-
tice guidance on the implementation of effective assertive outreach services and adaptation of 
health and social care settings to optimise on-site engagement  
In collaboration with registered professional bodies (including; RCGP, RCN, RCPsych, GPhC), public 
health bodies to develop value-based ‘AAS for healthcare professionals’ training and knowledge shar-
ing opportunities (including e-learning and GP cluster events). Products to be embedded as a core 
training programmes within NHS Trusts/Health Boards and community health services.
Adopting a ‘whole person’ approach, substance misuse commissioning boards to undertake a bienni-
al comprehensive network mapping and gap analysis exercise of local health and social care services 
accessible to individuals using AAS. The mapping and gap analysis exercise should include:
• Substance misuse and harm reduction
• Physical health, mental health and wellbeing
• Diet, nutrition, exercise and training advice 
• Sports injury
• Sexual health and wellbeing
This work should lead to the development of a local/regional service directory for dissemination via 
outreach services, local health and social care expert AAS fora and establishment of dedicated AAS 
health and well-being clinic sessions within existing services
Public health bodies and AAS leads to produce the following essential documents:
• A ‘What to expect’ document developed for distribution across gyms/fitness venues aimed at  
 owners, managers and staff on working with AAS outreach services
• Collation of all local/regional AAS health and social care directories for inclusion on national  
 websites e.g. IPEDInfo.co.uk
• A written statement on the implications and importance of AAS disclosure during a medical  
 consultation or treatment
Public health bodies in collaboration with UK wide academic institutions to undertake research to 
establish a robust prevalence estimate of AAS use and evidence of harms associated with use.
1.2 Recomendations
  
Evidence suggests there has been a rise in non-prescribed use and injection of image and 
performance enhancing drugs (IPEDs), particularly anabolic-androgenic steroids (AAS) and 
associated drugs, in the United Kingdom over recent decades. In particular, the estimated number 
of 16 to 59 year olds reporting lifetime use of anabolic steroids in the Crime Survey for England 
and Wales has increased from 194,000 in 2005/06 to 271,000 in 2015/16.1. The survey is likely to be 
unreliable for rare events like anabolic steroid use and so it may under-estimate the extent of their 
use; however, data from needle and syringe programmes also indicate that use of IPEDs is likely to 
be increasing. 2.
 
The motivations for using AAS and other associated IPEDs are varied, and these and the other 
drivers of use have probably changed over time. Among longer established groups of people 
using AAS and associated drugs, such as bodybuilders and strength athletes, who have been most 
studied, being “bigger, stronger” is typically the rationale. However, there are a wide range of issues 
impacting on use and a more complex picture of interrelated factors associated with body image, 
masculinity, psychological well-being and early influences has emerged.3. 4. 5.
     
The use of IPEDs, including AAS, for aesthetic purposes probably represents the most common 
driver of their use in the UK.6. Recent work to develop typologies of AAS use has identified four 
broad types of people using these drugs: the expert, the athlete, the wellbeing, and the 
YOLO (You Only Live Once) types (Figure 1).7. 8. Though these groupings are likely to need further 
refinement, they illustrate the heterogeneity of those using AAS and associated IPEDs.
There are a diverse range of IPEDs that are being used, these include, “fat burners”, tanning agents 
and a range of hormonal products designed to assist or accelerate physical or physiological 
changes, as well as AAS. Whilst some of these substances are recognised medical preparations, 
some are sold as ‘research chemicals’ with little or no clinical testing.10.  These drugs are frequently 
sourced illicitly. Evidence from testing of seized products shows a significant proportion are 
counterfeit or home produced, and as such; are of highly variable quality, may contain substances 
other than those reported on the label, have varying dose strengths, or have a high bacterial load; 
all of which can contribute to potential serious health risks and harms. 
A number of potential health risks have been identified with the use and injection of AAS and other 
associated IPEDs. Many well established harms of AAS are comparatively minor (e.g. acne), however 
other harms include more severe physical (e.g. cardiovascular disease, damage to the liver) and 
psychological (e.g. mood changes, increased aggression) problems.9. 10. 11. Many IPEDs, including 
AAS, can be injected, and so their use can lead to health issues that result from poor or unhygienic 
injection practice, including soft-tissue damage and infections.12. 13. 14.    
A lot of people I train with I know wouldn’t want 
to go to A&E or wouldn’t want to go to their 
doctor and they wouldn’t want any record of 
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Design: Human Enhancement Drugs Network, Birmingham City University, 
Public Health Institute (LJMU) and Aalborg Antidoping (Aalborg Municipality, DK)
Reference: Christiansen, Vinther & Liokaftos. 2016. 
Drugs: Education, Prevention and Policy, 1-11.

















THE WELL-BEING TYPE THE EXPERT TYPE
Motivated by impatience, curiosity and influence 
from peers and authoritative role models. 
Focus on asserting his masculinity (e.g. impressing 
girls and advancing upwards in the male hierarchy). 
Little to no concern about side 
effects and towards general health
Aims at immediate benefits. 
Low level of ‘steroid knowledge’ - 
based on lore and advice from ‘gym rats’ 
Risk-taking lifestyle (e.g. recreational drug use and
is more likely to end up in fights than the other types) 
Little concern about diet, training and recovery
Motivated by vanity and/or wishes 
for restoration or rejuvenation 
Focus on well-being, moderation and 
peer recognition (e.g. during summertime) 
Considers side effects and wants to play it safe 
Aims at slight improvements 
Medium level of knowledge – based on 
own experience, online fora and other users 
Wants to improve his quality of life 
and has a relaxed take on nutrition 
Focus on healthy living and are typically older 
Motivated by competitive aspirations
Focus on performance
(e.g., skills, size, and definition).
Concerned with side effects but willing to run 
health risks in order to fulfil sporting ambitions.
Aims at maximising benefits by combining 
different steroids (stacking) with other performance 
and image enhancing drugs (polypharmacy)
Medium to high level of knowledge – based on 
medical assistance and experience from his 
sporting community.
Plans training and diet according to season – 
avoids recreational drugs.
Dedicated to the athlete life style
Motivated by lay scientific curiosity and 
a fascination with pharmacological 
performance enhancement. 
Focus on muscularity, learning and
 knowledge sharing. 
Very concerned with side effects 
and wants to play it safe
Aims at optimising benefits with 
a perceived sensible drug regimen
High level of knowledge – based on 
various sources including scientific papers 
Values health and monitors his body 
systematically (e.g. in collaboration with physician) 
Offers advice on harm reduction to 
others and seeks recognition as a source 
of expertise on steroids. 
Design: Human Enhancement Drugs Network, Birmingham City University, 
Public Health Institute (LJMU) and Aalborg Antidoping (Aalborg Municipality, DK)
Reference: Christiansen, Vinther & Liokaftos. 2016. 
Drugs: Education, Prevention and Policy, 1-11.
More information is available at 
www.humanenhancementdrugs.com
Figure 1: A typology of men using anabolic-androgenic steroids and their risk by Christiansen, Vinther & Liokaftos (2016)
Whilst it is clear that there are harms associated with the use of AAS and associated IPEDs (figure 
2), the uptake of healthcare and prevention services related to these is often poor.15. Data indicates 
that people who use these drugs will often choose to either wait for symptoms to go away or self-
medicate with ‘natural remedies’, over the counter medication, or diverted pharmaceuticals.16. 17. 
18. For example, findings from the recent national IPED Info survey* indicated that more than half 
waited for symptoms of side-effects to go away on their own without seeking medical help/advice, 
and a third self-medicated.6. In part, this reluctance to use healthcare services is probably due 
people being cautious about disclosing their use of AAS and other IPEDs to professionals, and so 
using peers for advice on use, preventing harm and managing any side-effects.19.
Furthermore, people who use AAS and other IPEDs may not perceive themselves as a ‘drug user’, 
as they are not using psychoactive drugs including cocaine or heroin,20. and so may not access 
specialist drug services and harm reduction interventions such as needle and syringe programmes. 
Recent studies indicate that the levels of blood borne viral infections among those injecting IPEDs 
are higher than among the general population 21. and that worryingly many of these infections 
remain undiagnosed.22. Thus, there is a need to improve access to health and prevention services for 
this group.23.
People who use AAS and other IPEDs can experience a range of preventable acute and chronic 
health problems due to the effects of the substances they use on their bodies. These potential 
harms could be reduced through regular metabolic testing and prompt health care seeking in 
response to symptoms of a possible problem. The little available evidence indicates that regular 
metabolic testing is limited, and typically done privately, and those using IPEDs may not always 
recognise symptoms or readily access health services in response to these.
In addition to the harms associated with the use of AAS and other IPEDs, evidence indicates a range 
of additional risk behaviours common amongst some of those using these drugs including sexual 
risk taking (Figure 2), which may result in sexually transmitted infections, psychoactive drug use and 
high alcohol consumption levels.6. 
>
4
* Available at: http://www.ipedinfo.co.uk/resources/downloads/2016%20National%20IPED%20Info%20Survey%20report%20FINAL.pdf
Figure 2: National IPED Info Survey findings 
infographic.  Public Health Institute & Public Health 
Wales (2016)
To take part in our 2016 survey visit www.ipedinfo.co.uk or ask:
 
Survey closes December 1st 2016.
* Statistics taken from Hope, VD et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs:  
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IPEDS 2015 SURVEY RESULTS
ipedinfo.co.uk
This report presents the key findings and recommendations from a research study that aimed to 
evidence the barriers and facilitators to accessing health services among people injecting AAS 
and other associated IPEDs. The focus of this work was to identify low cost/no cost (that is at a cost 
between £0 and £5K per annum) service delivery modifications that could improve the availability 
and acceptability of prevention initiatives and early health care interventions for this group. 
These interventions should aim to address one or more areas of health, including physical and 
psychological health and well-being, injecting site infection, injury identification and treatment 




2.2 Th  tudy
 
This study utilised three data collection activities involving people from across Wales.  
Two sets of semi-structured qualitative interviews explored understandings of the harms associated 
with using AAS and other associated IPEDs, and the barriers and facilitators to accessing health 
services, involving:
a. Individuals using anabolic–androgenic steroids
b. Individuals providing community-based health and related services that should be accessed by 
    this group.
An Evidence Gathering and Synthesis Event which involved a wide range of stakeholders including 
providers of a range of NHS primary and secondary care services 
Recruitment for the two sets of interviews took place in a number of selected local areas across 
Wales. Though these were pragmatically selected, they were geographically diverse reflecting a mix 
of urban and more rural settings. Participants in the Evidence Gathering and Synthesis Event were 
from across Wales. This study was approved by LJMU Research Ethics Committee.
The semi-structured interviews with men aged 18 years or over who were using AAS were 
conducted face-to-face. Participants were recruited from three regions in Wales; North East Wales, 
South and South East Wales Valleys, and Cardiff. The recruitment approach aimed to include 
participants who were using AAS for: ‘occupational’ reasons, those engaged in amateur competitive 
sport, and those whose use was for aesthetic purposes.
Participants were recruited in each area through individuals working in community settings and 
in specialist gyms who come into contact with people who are using AAS. These individuals acted 
as ‘gatekeepers’ introducing possible participants to a researcher and/or facilitated the study 
researcher’s access to recruitment settings.
 
Interviews were undertaken between autumn of 2017 and summer of 2018, and were usually audio 
recorded, where the participant didn’t want to be recorded detailed field-notes were made. All 
participants provided written consent before being interviewed, and could opt out of the study at 
any point.
 
The interviews were undertaken by trained researchers in a private safe space, convenient for the 
interviewee and lasted between 30 and 75 minutes. An agreed topic guide was followed during the 
interviews that explored their use AAS and other IPEDs, their knowledge and experience of harms 
related to use of these and health service engagement. 
A total of 17 participants were recruited from three regions in Wales; North East Wales (5), South and 
South East Wales Valleys and Cardiff (12). There ages ranged from 20 years to 53 years old. 
The participants report durations of AAS use that varied from a couple of years to several decades. 
All of the participants were men, and they included people who were using AAS for ‘occupational’ 
reasons, those engaged in amateur competitive sport, and those whose use of anabolic–androgenic 
steroids was for aesthetic purposes. Of the interviews, 13 were audio recorded and detailed field-
notes were made for the four who declined to be recorded.
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3  Method & Participants
1. 
2. 
3.1 Interviews with people using anabolic–androgenic steroids (AAS)
3.1.1 The participants 
Semi-structured interviews were undertaken with invited individuals who were employed in, or 
led, community-based health, social care or related services that were being, or could have been, 
accessed by people who use AAS. These interviews lasted between 30 and 45 minutes, and were 
conducted either face-to-face or, when this was not practical, by telephone.
A list of relevant service providers was accessed through Public Health Wales and service directories. 
Those identified were initially emailed information about the study. Agreement to participate 
and the arrangements for interview was then established via telephone. All participants provided 
written consent before their interview, and were able to opt out of the study at any point.
The interviews were conducted by a trained researcher in a private and safe environment, usually 
at the person’s place of work. Semi-structured interviews were then completed following an agreed 
topic guide which explored: their role in current service provision, their knowledge of the use of 
AAS and other IPEDs, and their understandings of possible barriers and facilitators to service access.
The interviews were digitally recorded, and the researcher took additional field notes as needed 
to support the interview process. The recordings themselves were used in the analyses, alongside 
interview notes.
Interviews were completed with eight service providers during the autumn of 2017 and the winter 
of 2018. Participants worked in a range of settings including, needle and syringe programmes, 
drug use related outreach, community pharmacists, and professionals involved in the provision 
of community based sport and fitness related healthcare. All were currently working in roles that 
involved direct contact with people using IPEDs, and had been in their current role for at least 
several years.
The Evidence Gathering and Synthesis Event for the study was held in Cardiff on the 7th November 
2018. It brought together a range of people including those from healthcare, public health, and 
the drug use fields, with people who had experience of using AAS and gym owners. Its overall 
aim was to explore options for service delivery developments that could improve the uptake of 
health services by those using AAS and other IPEDs for acute health issues; the prevention of health 
problems; and providing harm reduction interventions. The focus was on practical and low cost 
ideas for service delivery developments.
The day operated under the ‘Chatham House Rule’ to encourage frank and open discussion. 
Participates didn’t have name badges and they were not provided with a list of fellow participants.
The Evidence Gathering Event was structured on the COM-B behaviour change model. The first part 
of the day involved structured mixed groups discussions to explore issues impacting on service 
uptake using the following four questions:
Question 1: Can you identify, explain and discuss lifestyle factors or behaviours that may influence early 
engagement amongst IPED users for physical, psychological and social/relationship issues?
Question 2: Can you identify, explain and discuss social and environmental factors that may influence 
early engagement amongst IPED users for physical, psychological and social/relationship issues?
7
3.2 Interviews with those providing services
3.2.1 The participants
3.3 Evidence Gathering & Synthesis Event
8
Question 3: Can you identify, explain and discuss policy and practices (of providers) that may influence 
early engagement amongst IPED users for physical, psychological and social/relationship issues?
 
Question 4: Can you identify, explain and discuss access and quality issues within existing health and 
related services that may influence early engagement amongst IPED users for physical, psychological 
and social/relationship issues?
The discussion in each group was led by an experienced facilitator and a scribe took detailed notes, 
and as needed asked the group to validate the recording of key points. After the groups session all 
participants came together for an interactive feedback session to allow reflection on the groups’ 
discussions.
After lunch the key findings from the two sets of interviews undertaken as part of this study (see 
sections 3.1 and 3.2 above) were then presented and then discussed. Service delivery developments 
that were generated from both the interviews and during the group work in the morning were 
then developed by the study team into a set of suggested outline options for service delivery 
developments and improvements. The participants were then asked to vote on whether they 
supported each of these using an anonymous interactive smart phone application. The voting 
choices for each of the suggested options were: ‘Strongly Agree’, ‘Agree’, ‘Disagree’, or ‘Strongly 
Disagree’.
  
In this section the conclusions arising from the study findings are presented. A summary of findings 
from the semi-structured interviews conducted with people using AAS, service providers and the 
Evidence Gathering and Synthesis Event that underpin these conclusions and the recommendations 
are also presented within this section.
Findings have been categorised and tabulated into the following core themes: 
•  Motivations, knowledge and information 
•  Identity, stigma and relationship with services
•  Service delivery, practices and policy
In addition, the preliminary recommendations for service improvements that developed from the 
interviews and during the Evidence Gathering and Synthesis Event have been summarised in this 
section. 
Both the observations and evidence related to the first theme Motivations, knowledge and 
information from qualitative interviews with people using AAS, service providers and the Evidence 
Gathering and Synthesis Event discussions are detailed in Table 1 (T1). 
In this study a wide range of motivations were reported by the participants using AAS which 
had contributed to the initiation and continuation of use; these included meeting sporting or 
body building goals, but also confidence and body image issues. A common theme was that 
the motivations for using AAS and other IPEDs change throughout someone’s life, making 
categorisation difficult and dependent on other life goals, physical and mental health at the time. 
Perceptions amongst service providers about why people used AAS and other IPEDs were 
often related to the types of clients they had engaged with. Overall the participants felt that 
the predominant group of people using AAS and other IPEDs were those using these drugs for 
aesthetic enhancement purposes. Use of these substances for aesthetic enhancement was seen 
as a reflection of the increasing social pressures related to male body image. These pressures were 
perceived by services as being widespread in society generally, but also as being important within 
many social networks and in gym and fitness environments [T1 row 1.1]. 
Knowledge and information surrounding both the short and long term effects of AAS use was 
typically well recognised amongst the interviewed participants using AAS. However, perceptions 
of safety were often relativized in the context of the use of other substances, participating in other 
healthy lifestyle behaviours (e.g. weight training and exercise, managed diet), and taking personal 
responsibility around their use [T1 rows 1.2, 1.3]. 
9
4 Findings and observations
4.1 Motivations, knowledge and information
4.1.1 Motivations for use
4.1.2 Perceived risk and harms
Amongst service providers, the accessibility of reliable and appropriate knowledge and information 
related to the use and effects of AAS and other IPEDs by those using or thinking about use, was 
another common theme [1.2]. There were concerns that many people using these drugs relied on 
internet forums, websites, their peers, and their ‘dealers’ for information about what to use and how 
to use AAS and other IPEDs. Information from these sources, though sometimes robust, is often 
incomplete, and sometimes inaccurate and misleading. Furthermore, sexual health risks and risk of 
blood borne viral infection were often underestimated. It was felt making access to reliable, neutral 
and scientifically based information was seen as an important area for action. Such information 
is available on a number of websites, though these sites may need some further development to 
ensure they are up-to-date, engaging and accessible. It was suggested that better signposting of 
people to these reliable sources of information using a range of means would be useful. 
All interviewed participants using AAS had experienced or witnessed harmful effects linked in part 
or fully to the use of AAS. Whilst the potential impact of such side effects were recognised by most, 
in some cases impact was trivialised or disregarded [T1 row 1.4]. In the main, the management 
of side effects varied depending on its perceived nature by the individual. For example, effects 
perceived as cosmetic in nature (e.g. gynecomastia, acne, testicular atrophy) tended to be self-
treated, whereas most felt they would seek medical advice for more serious side-effects that 
involved major organs [T1 row 1.5]. Discussions between service users and service providers 
surrounding side-effects often related to cosmetic and acute health effects rather than long term 
impacts associated with use.
          
Concerns were raised within all participant groups about the levels of knowledge and 
understanding of the use of AAS and other IPEDs amongst those delivering services that are, or 
should be, being used by people using AAS and other IPEDs. There were particular concerns in 
relation to those staff working in pharmacies providing needle and syringe programmes, due to 
the high staff turnover and limited time for training, and also amongst primary care providers. It 
was suggested training should be available through easy to access routes, such as, online courses 
including refresher training. The training should cover approaches to effective engagement with 
this group, in addition to providing understandings of the reasons for, and nature of, AAS and other 
IPED use.





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study a wide range of motivations were reported by the participants using AAS which 
had contributed to the initiation and continuation of use; these included meeting sporting or 
body building goals, but also confidence and body image issues. A common theme was that 
the motivations for using AAS and other IPEDs change throughout someone’s life, making 
categorisation difficult and dependent on other life goals, physical and mental health at the time. 
The observations and evidence related to the second theme Identity, stigma and service 
engagement from qualitative interviews with participants using AAS, service providers and 
Evidence Gathering and Synthesis Event discussions are summarised in Table 2 (T2). 
It was clear from both the interviews with people using AAS and those delivering services, as well 
as from the evidence gathering event, that issues related to stigma, particularly embarrassment, 
about the use of AAS and other IPEDs was an important issue for people using these drugs [T2 rows 
2.1, 2.3]. People using AAS and other IPEDs were concerned about disclosing their use of these 
drugs, this was often related to being concerned about people judging them and being stigmatised 
because of their use of these drugs. A key consequence of this was a reluctance to engage with 
services, particularly if these services, or some service staff, were felt to be unknowledgeable or 
perceived as potentially being judgemental. 
Further exploration of the embarrassment experienced by participants using AAS, observed that 
such feelings tended to manifest themselves during specific points within their AAS using career. 
In most cases, this was at the point of needing to seek health care advice due to realised health and 
wellbeing concerns linked to their AAS use. Such individuals described themselves as educated 
and knowledgeable around potential side effects and yet had made a confident decision to use. 
However, where they had found themselves in a situation where their use had resulted in them 
suffering from adverse effects it was at this point participants said they felt/would feel embarrassed 
[T2 row 2.3]. 
The findings indicate that service engagement strategies for this group will probably be most 
effective if they focus on ensuring staff have an understanding of the reasons and drivers for the use 
of AAS and other IPEDs [T2 row 2.2]. Individuals interviewed who were using AAS claimed that they 
often felt that their motivations for use were misunderstood, seen as a way of “cutting corners”, and 
little acknowledgment was placed on the diet and training regimes that accompany use. It was felt 
that staff who have some understanding of the reasons as to why people use these drugs will offer a 
more empathetic, non-judgemental and understanding service. 
14
4.2 Identity, stigma, and service engagement















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The observations and evidence related to the third theme Service delivery, practices and policy 
taken from qualitative interviews with participants using AAS, service providers and Evidence 
Gathering and Synthesis Event discussions are detailed in Table 3 (T3). 
A range of issues related to service accessibility and acceptability were noted, including service 
opening times, service locations, and the environments in which services were provided.  
For many of the participants interviewed who were using AAS, the topic of confidentiality and the 
fear of their use of AAS and other IPEDs being recorded within medical records and notes was seen 
as a significant barrier in engaging with healthcare services [T3 row 3.1]. Their concerns ranged from 
the fear of being judged at a later date to medical records being passed to employers occupational 
health departments. This has led to a number of approaches being adopted amongst those 
individuals including; self-treatment of minor side effects, use of online services to access blood 
testing and injecting paraphernalia [T3 row 3.3].
 
There were varying opinions on whether co-provision of services for those using AAS and other 
IPEDs alongside those for people using psychoactive drugs was appropriate [T3 row 3.2]. Provision 
of stand-alone services with separate infrastructure is likely to be costly, and probably not 
sustainable where these would be delivering similar interventions to those provided to people 
using psychoactive drugs, such as, the provision of clean sterile injecting equipment through 
needle and syringe programmes. However, in relation to more specialist services focused on IPED 
specific issues, standalone services may be more practical if these were hosted within generic 
services. The form and practicalities of such services needs further examination, but the recent 
development of such a service in Newport, Gwent provides a possible model. The development of 
such service requires further exploration of a range of delivery models, for example, shared care 
systems with GPs and e-clinics. Such methods could facilitate ease of access to specialist services 
across Wales, particularly in rural areas.
The resultant problems with engagement was a very common concern raised repeatedly during 
the study. Participants suggested various approaches that could be used to improve engagement 
with services; however, the provision of services by informed, empathetic, and non-judgemental 
staff was seen as being key to improving engagement [T3 row 3.4]. Some participants indicated 
that service staff were sometimes overly concerned about not having a complete understanding 
of the nature of the drugs involved and their use; however, in many settings such knowledge is not 
necessary to engage with this group. For example, in needle and syringe programmes focusing 
on harm reduction and practical messages related to injection technique could be an effective 
approach to engagement. In relation to engaging clients about testing for sexually transmitted 
and blood borne viral infections, discussions focused around sexual risks are probably a more 
appropriate and effective approach, than discussions related to risk of infection transmission 
through injecting.
The use of outreach approaches to access people using AAS and other IPEDs, or who might be 
thinking about using these drugs, in gyms and other fitness venues was felt to be particularly 
important; however, there are a number of barriers to this, in particular gaining the support of the 
venue owners [T3 row 3.3]. Such outreach activities may be particularly effective if they involve 
credible messengers and peers in their delivery. 
18
4.3 Service delivery, practices and policy
4.3.1 Barriers and facilitators to service engagement
For Table 3 - see overleaf.
The provision of more generic well-being services – either through outreach or in fixed sites – 
focusing on health, wellbeing and fitness, particularly if targeted at young people, may have a role 
preventing use and supporting other approaches to fitness, such as, diet and training, as well as 
reducing harm among those who go on to use AAS and other IPEDs.
Related to this, there was concern among those providing services about the lack of access to 
metabolic testing and treatment interventions for those using AAS and other IPEDs, as currently 
there are no approved treatment interventions [T3 row 3.5]. Concerns about the provision of, 
and access to, care for mental health issues for those using IPEDs was very common among the 
participants. Mental health issues may underpin the use of AAS and other IPEDs for some people, 
and so being able to address these issues is an important aspect of an effective response. 
From a policy perspective, service providers and evidence gathering event attendees were 
particularly concerned about the lack of guidance in relation to providing services to those who 
use IPEDs, and the related lack of clear and well-defined care and referral pathways for them [T3 
row 3.7]. It was suggested this needs to be addressed through development of guidelines on 
appropriate responses to the use of AAS and other IPEDs for health and wellbeing service providers. 
There was also support for the provision of guidance to the operators of gyms and fitness venues 
so as to support outreach, harm reduction interventions, and early identification of those who are 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Throughout the course of the interviews with participants using AAS, service providers, and the 
Evidence Gathering and Synthesis Event a range of recommendations for service improvements 
were suggested for wider discussion and consideration. These are summarised below.
•  Making it easier for those using AAS and other IPEDs to access reliable and accurate 
 information. Information  needs to be modern and relevant, appropriately targeted and 
 engaging and available in a range of formats 
•  Improve staff skill set through engagement skills training specific to working with those 
 who use AAS and other IPEDs, or who are thinking about doing so 
•  E-learning, particularly for pharmacy counter staff on key issues related to the use of AAS 
 and other IPEDs and engaging with those who use these drugs 
•  Better training of, and engagement with, primary care staff particularly GPs. If GPs engaged 
 effectively with those using AAS and other IPEDs, then they could provide a route to 
 accessing metabolic testing and   psychiatric interventions, as well as responding to 
 concerns about acute and chronic harms.
Development of specialist care services 
•  Development of clear healthcare guidelines for providing services to those using AAS and  
 other IPEDs
•  The provision of more specialist services for those using AAS and other IPEDs was   
       suggested.  In particular doctor led specialist clinics for those using these drugs. It was 
 suggested that this could be a virtual specialist GP led clinic with shared care agreements
•  To develop awareness of, and improve responses to, the use of AAS and other IPEDs it was 
 suggested that  GPs with specialist interest and knowledge meet quarterly within cluster 
 protected education time (CPET)  meetings – so that they could receive training from GP to 
 GP.
Development of existing harm reduction services 
•  Aim to make service offer appear more engaging to those using AAS and other IPEDs.    
 Engagement should be about offering something that those using AAS and other IPEDs  
 want – such as providing advice on diet or fitness, or access to metabolic testing – and using  
 this to draw people into services so that other interventions can also be delivered
•  Focusing interactions in generic settings, such as needle and syringe programmes, on   
 injecting, sexual, alcohol and ‘lifestyle’ risks rather than the drug(s) being used 
•  Making existing services more acceptable and accessible to those using AAS and other  
 IPEDs, this could include changes to opening hours, offer of specialist sessions, or a more  
 careful approach to providing broad based drug services as well as improving outreach.
Developing other professional networks
•  Closer working between services, with clear ‘care’ pathways for those using AAS and other  
 IPEDs 
•  Improving access to mental health support for those using AAS and other IPEDs through a  
 range of routes 
•  Closer working with Sexual Health Services in relation to testing for sexually transmitted  
 infections and blood borne virus and for access to vaccinations. This should include   
 awareness raising among staff of Sexual Health Services to support them in identifying  
 those using AAS and other IPEDs. This will provide opportunities within these services for  
 referral and advice provision related to use of IPEDs.
25
4.4 Suggested recommendations for service improvement
Education and awareness raising 
26
Community and peer to peer approaches 
•  The development of a common document for use by all gyms with ‘dos and don’ts’ for   
 responsible, safer use of supplements, AAS and other IPEDs. With use of this enforced, i.e. gym  
 licenses mandate on displaying harm reduction information
•  Increasing engagement of those using AAS and other IPEDs with services through the use of  
 social media and outreach into gyms
•  Develop a peer based network to provide information and harm reduction to those using AAS  
 and other IPEDs – as well chosen peers would be seen as credible messengers 
•  One respondent suggested consideration be given to co-payment for metabolic testing when  
 this was used for physiological monitoring during periods of use. The co-payment would cover  
 only the actual cost of the test advice and interpretation provided by NHS.  However, this  
 approach could be problematic in relation to equity of service access.
The suggestions and ideas for possible service developments and improvements that arose either 
during the two sets of semi-structured interviews or during the discussions that took place during 
the morning of the Evidence Gathering and Synthesis Event were collated and compared. 
These suggestions were condensed and presented to those attending the Evidence Gathering and 
Synthesis Event for feedback. To explore consensus for each service improvement and development 
options, the participants used an anonymous online voting app to indicate if they either “Strongly 
Agreed”, “Agree”, “Disagree”, or “Strongly Disagree” with each option. The number of participants 
voting on each suggestion varied slightly, with between 25 and 28 valid votes per option. See 
Figure 3 for voting outcomes for each service improvement and development recommendation. 
The proportion indicating agreement (that is voting for either Strongly Agree or Agree) with the 
development and improvement options ranged from 20% to 100%. There were only two options 
with less than 60% agreement.  There were four options where agreement was between 60% and 
70%, and eight with 100% agreement.
 
The option with least support – with only 20% indicating agreement – was “Co-payment for 
metabolic testing for monitoring health”. There would seem to be little support for this option, and 
for taking this idea further at this time.
Eight options in total had 100% agreement, and considering this high level of support these service 
development and improvement options should therefore be considered for further development 
and implementation. 
4.5 Consensus on preliminary recommendations for service 
        improvement and development
0%           20%           40%          60%          80%        100%
Development and wider promotion of awareness raising 
products in various formats including information leaflets, QR 
code business cards provided in a range of environments and in 
online packs; signposting to credible online info.
Practitioners need to focus on wider health and well-being issues 
including psychological health as intervention, NOT soley on the drugs.
Development of e-learning module on IPEDs for Primary and 
Secondary Care services including GPs, Pharmacy
Development of General Practitioner to General Practitioner 
IPED training model within cluster.
Produce short film on how to engage with individuals using IPEDs.
Dedicated needle and syringe programme staff in all needle  and 
syringe programme sites including pharmacy with increased 
flexible opening hours.
Improved networking and communication between and within service 
types (all needle and syringe programmes, all IPED health and allied 
professionals/services etc); development of local forums.
Establish consistant targeted and tailored health and well-being 
outreach services (including needle and syringe programmes) 
co-delivered by health care services and peer champions.
Establish an IPED user group to scope and design an interactive 
app (eg - cycle and training diaries) to promote engagement.
Development of targeted/specialist services which aims 
to address wider well-being including: fitness, diet and 
supplementation - perhaps tie in with reducing obesity and 
other public health programmes.
The development of a virtual General practitioner or IPED clinic available 
online - utilising contemporary digital health approaches.
Figure 3: Extent of consensus with the service development and improvement recommendations 
generated: result of voting during Evidence Gathering and Synthesis day
Strongly Agree Agree Disagree Strongly Disagree
>
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0%           20%           40%          60%          80%        100%
Increased General Practitioner prescribing of IPED/Hormone 
Replacement Therapy in response to long term complications 
associated with IPED use.
Tailoring of bacterial infection amd wound care initiatives e.g. ACT 
(Act - Care - Treat) project to individuals using IPEDs.
Introduction of co-payment system for metabolic testing for 
monitoring health associated with IPED use.
Increased/routine availability of drug testing services e.g. 
expansion of WEDINOS to submissions of IPEDs in Wales.
Increase availability of cardiac and wider health care screening 
(e.g. ECG testing) within health and well-being clinics.
National roll out of specialist IPED Clinics with inclusion of 
metabolic testing e.g. South Wales IPED Clinic model delivered in 
Newport (encouraging inclusion of significant others).
Establish a formal evidenge briefing on male Hormone Replacement 
Therapy for health professionals (and associated others).
Formally recognise IPEDs as a substance group linked to 
addiction/dependency.
Develop and publish written statement in order to clarify 
consequences of disclosing IPED use to medical practitioner and 
legal context of possession/insurance.
increase engagement with gyms and development of initiatives 
to improve promotion of harm reduction informastion e.g. 
mandatory condition of gym licenses to displaying harm 
reduction information.
improved engagement within gym settings - development of 
a common guidance document with “do’s and don’ts” for harm 
reduction and safer use.
Figure 3 continued.
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Strongly Agree Agree Disagree Strongly Disagree
 
The following recommendations draw upon data generated and collated as part of this study. 
However, they are principally informed by the ideas generated and voted on at the end of the 
Evidence Gathering and Synthesis Event. The following recommendations are based on those 
options that had widespread support throughout this project:
Government bodies, academic institutions and health services to provide resources and undertake 
a review with the aim of developing the evidence base on the use of online technologies (including 
social media) to facilitate effective health service engagement and e-clinics. This work should 
include online advice and triage clinics targeted towards young people using AAS currently not 
engaged with existing services
Public health bodies, community substance misuse leads and commissioners to develop best 
practice guidance on the implementation of effective assertive outreach services and adaptation of 
health and social care settings to optimise on-site engagement    
In collaboration with registered professional bodies (including; RCGP, RCN, RCPsych, GPhC), public 
health bodies to develop value-based ‘AAS for healthcare professionals’ training and knowledge 
sharing opportunities (including e-learning and GP cluster events). Products to be embedded as a 
core training programmes within NHS Trusts/Health Boards and community health services  
Adopting a ‘whole person’ approach, substance misuse commissioning boards to undertake a 
biennial comprehensive network mapping and gap analysis exercise of local health and social care 
services accessible to individuals using AAS. The mapping and gap analysis exercise should include:
• Substance misuse and harm reduction
• Physical health, mental health and wellbeing
• Diet, nutrition, exercise and training advice 
• Sports injury
• Sexual health and wellbeing
This work should lead to the development of a local/regional service directory for dissemination via 
outreach services, local health and social care expert AAS fora and establishment of dedicated AAS 
health and well-being clinic sessions within existing services
Public health bodies and AAS leads to produce the following essential documents:
•  A ‘What to expect’ document developed for distribution across gyms/fitness venues aimed  
 at owners, managers and staff on working with AAS outreach services
•  Collation of all local/regional AAS health and social care directories for inclusion on national  
 websites e.g. IPEDInfo.co.uk
•  A written statement on the implications and importance of AAS disclosure during a medical  
 consultation or treatment
Public health bodies in collaboration with UK wide academic institutions to undertake research 
to establish a robust prevalence estimate of AAS use and evidence of harms associated with use.
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